Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
876 results about "Neoplastic disease" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Neoplastic disease. A neoplasm is an abnormal growth of cells, also known as a tumor. Neoplastic diseases are conditions that cause tumor growth — both benign and malignant. Benign tumors are noncancerous growths. They usually grow slowly and can’t spread to other tissues. Malignant tumors are cancerous and can grow slowly or quickly.
Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
Thiazolo-, oxazolo- and selenazolo[4,5-c]quinolin-4-amines and analogs thereof are described including methods of manufacture and the use of novel intermediates. The compounds are immunomodulators and induce cytokine biosynthesis, including interferon and / or tumor biosynthesis, necrosis factor, and inhibit the T-helper-type 2 immune response. The compounds are further useful in the treatment of viral and neoplastic diseases.
Owner:3M INNOVATIVE PROPERTIES CO
Method for cryospray ablation
InactiveUS20090192505A1Increase load capacityAdequate doseUltrasonic/sonic/infrasonic diagnosticsEchographic/ultrasound-imaging preparationsThoracic structureDisease
The present invention relates to methods for treating tissue in the thoracic cavity of a subject by the application of a cryogen, or using the cryogen to create an isotherm in proximity to the tissue to be treated. A wide variety of conditions may be treated using the methods of the invention including asthma, neoplastic disease and a variety of conditions characterized by inflammation in lung and chest tissue.
Owner:RESET MEDICAL
Compositions and methods for treatment of neoplastic disease
InactiveUS20050112141A1High productFacilitates their targetingFusions for specific cell targetingReceptors for cytokines/lymphoines/interferonsAbnormal tissue growthDisease
The present invention comprises compositions and methods for treating a tumor or neoplastic disease in a host, The methods employ conjugates comprising superantigen polypeptides or nucleic acids with other structures that preferentially bind to tumor cells and are capable of inducing apoptosis. Also provided are superantigen-glycolipid conjugates and vesicles that are loaded onto antigen presenting cells to activate both T cells and NKT cells. Cell-based vaccines comprise tumor cells engineered to express a superantigen along with glycolipids products which, when expressed, render the cells capable of eliciting an effective anti-tumor immune response in a mammal into which these cells are introduced. Included among these compositions are tumor cells, hybrid cells of tumor cells and accessory cells, preferably dendritic cells. Also provided are T cells and NKT cells activated by the above compositions that can be administered for adoptive immunotherapy.
Owner:TERMAN DAVID
Treatment of neoplasms with viruses
InactiveUS20030044384A1Convenient treatmentReduce productionSsRNA viruses negative-senseBiocideDiseaseAnti viral response
The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy.
Owner:PRO VIRUS
Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
InactiveUS20050192248A1Enhancement and extension of durationBiocideOrganic active ingredientsDiseaseAdjuvant
The present invention relates to methods and compositions for augmenting an immunogenicity of an antigen in a mammal, comprising administering said antigen together with an adjuvant composition that includes a synthetic glycolipid compound of Formula I, as described herein. According to the present invention, the use of a compound of Formula I as an adjuvant is attributed at least in part to the enhancement and / or extension of antigen-specific Th1-type responses, in particular, CD8+ T cell responses. The methods and compositions of the present invention can be useful for prophylaxis and treatment of various infectious and neoplastic diseases.
Owner:NEW YORK UNIV +1
Methods and compositions for determining neoplastic disease responsiveness to antibody therapy
InactiveUS20030219818A1Microbiological testing/measurementDisease diagnosisFollicular lymphoma grade IIWilms' tumor
Methods are provided for determining whether a subject suffering from a neoplastic condition, e.g., non-Hodgkin's lymphoma (NHL), such as follicular lymphoma, is responsive to antineoplastic therapy, such as antibody therapy, e.g., Rituximab. In practicing the subject methods, an expression profile is obtained from the subject suffering from NHL and employed to determine whether the subject is responsive to antineoplastic therapy. In addition, reagents and kits thereof that find use in practicing the subject methods are provided.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Methods and systems for direct electrical current stimulation as a therapy for cancer and other neoplastic diseases
A small implantable stimulator(s) includes at least two electrodes for delivering electrical stimulation to surrounding tissue. The small stimulator provides means of stimulating a neoplasm with direct electrical current, such as relatively low-level direct current, without the need for external appliances during the stimulation session. The stimulator may be configured to be small enough to be implanted entirely within a neoplasm. Open- and closed-loop systems are disclosed.
Owner:BOSTON SCI NEUROMODULATION CORP
Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
InactiveUS6017540AEnhancing host 's immunocompetenceHigh activityBiocidePeptide/protein ingredientsStress ProteinsIn vivo
The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. "Antigenic molecule" as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens / immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic / immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.1 to 9.0 micrograms for complexes comprising hsp70, 5 to 49 micrograms for hsp90, and 0.1 to 9.0 micrograms for gp96.
Owner:FORDHAM UNIVERSITY
Immunostimulatory Combinations for Vaccine Adjuvants
This invention discloses immunostimulatory combinations of Tumor Necrosis Factor Receptor Superfamily (TN-FRSF) agonists, Toll-Like Receptor (TLR) agonists, “domain present in NAIP, CIITA, HET-E, TP-I (NACHT)-Leucine Rich Repeat (LRR)” or “NLR” agonists, RIG-I-Like Helicase or “RLH” agonists, purinergic receptor agonists and cytokine / chemokine receptor agonists, together with delivery methods. The combinations, when used alone at the site of pathology, provide immunostimulation that induces host humoral and cellular immunologic responses to eliminate pathogens or neoplasms. Alternatively, when the combinations are used with a defined antigens, these combinations can induce focused humoral and cellular immunologic responses useful as prophylactic and / or ameliorative therapeutic modalities for infections and the treatment of neoplastic disorders.
Owner:RGT UNIV OF CALIFORNIA
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
InactiveUS20080025980A1Induces proliferation and activationAvoids adverse immunogenic responseHybrid immunoglobulinsAntiviralsDiseaseAntiendomysial antibodies
Owner:CURETECH LTD +1
Microbial production of mature human leukocyte interferons
Owner:GENENTECH INC +1
Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols
Compositions and methods for the prevention and treatment of neoplastic diseases are described. Individuals at a high risk of developing or having neoplasia undergoing conventional therapies may be treated with an effective dose of triterpene derivatives in limonoids, polyphenolic flavonoid compounds, tocotrienols or a combination of these agents.
Owner:INTERHEALTH NUTRACEUTICALS
Treatment of neoplasms with viruses
InactiveUS20030165465A1Less weight lossConvenient treatmentSsRNA viruses negative-senseBiocideDiseaseAnti viral response
The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy.
Owner:WELLSTAT BIOLOGICS CORP
Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
InactiveUS20020183385A1Improve the quality of lifeRestricted blood flowHeavy metal active ingredientsBiocideDiseaseAbnormal tissue growth
The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
Owner:POLARX BIOPHARM
Oxazolo, thiazolo and selenazolo [4,5-c] quinolin-4-amines and analogs thereof
![Oxazolo, thiazolo and selenazolo [4,5-c] quinolin-4-amines and analogs thereof](https://images-eureka.patsnap.com/patent_img/74ac572b-d35d-49e9-8ac6-b860065b1a3c/US06323200-20011127-C00001.png "Oxazolo, thiazolo and selenazolo [4,5-c] quinolin-4-amines and analogs thereof")
![Oxazolo, thiazolo and selenazolo [4,5-c] quinolin-4-amines and analogs thereof](https://images-eureka.patsnap.com/patent_img/74ac572b-d35d-49e9-8ac6-b860065b1a3c/US06323200-20011127-C00002.png "Oxazolo, thiazolo and selenazolo [4,5-c] quinolin-4-amines and analogs thereof")
![Oxazolo, thiazolo and selenazolo [4,5-c] quinolin-4-amines and analogs thereof](https://images-eureka.patsnap.com/patent_img/74ac572b-d35d-49e9-8ac6-b860065b1a3c/US06323200-20011127-C00003.png "Oxazolo, thiazolo and selenazolo [4,5-c] quinolin-4-amines and analogs thereof")
Owner:3M INNOVATIVE PROPERTIES CO
Compositions and methods using complexes of heat shock protein 90 and antigenic molecules for the treatment and prevention of neoplastic diseases
Owner:FORDHAM UNIVERSITY
Microbial production of mature human leukocyte interferons
Disclosed herein are methods and means of microbially producing, via recombinant DNA technology, mature human leukocyte interferons, useful in the treatment of viral and neoplastic diseases.
Owner:F HOFFMANN LA ROCHE & CO AG +1
Methods for treatment of cancer or neoplastic disease and for inhibiting growth of cancer cells and neoplastic cells
The present invention provides methods for treating or preventing cancer or neoplastic disease comprising administering to a patient a compound having the features of a pharmacophore for human anti-apotptotic Bcl protein inhibitors or identified by the in vitro methods for identifying anti-apotptotic-Bcl protein inhibitors. Also disclosed are methods for inhibiting the growth of a cancer cell or a neoplastic cell, comprising contacting the cancer cell or neoplastic cell with a compound having the features of a pharmacophore for human anti-apoptotic-Bcl protein inhibitors.
Owner:GEMIN X BIOTECHNOLOGIES INC
HDAC inhibiting derivatives of camptothecin
InactiveUS20130281402A1Improve efficacyIncreased toxicityBiocideSilicon organic compoundsDiseaseHydroxamic acid
The disclosure includes hydroxamic compounds of Formula I: (Formula I) wherein Z, L, R1, R2, and R3 are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compounds.
Owner:CRYSTAL BIOPHARML LLC
Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
InactiveUS6156302AEnhancing host 's immunocompetenceHigh activityBiocideOrganic active ingredientsDiseaseInterleukin 6
The present invention relates to methods and compositions for enhancing immunological responses and for the prevention and treatment of infectious diseases or primary and metastatic neoplastic diseases based on the administration of macrophages and / or other antigen presenting cells (APC) sensitized with heat shock proteins non-covalently bound to peptide complexes and / or antigenic components. APC are incubated in the presence of hsp-peptide complexes and / or antigenic components in vitro. The sensitized cells are reinfused into the patient with or without treatment with cytokines including but not limited to interferon- alpha , interferon- alpha , interleukin-2, interleukin-4, interleukin-6 and tumor neurosis factor.
Owner:FORDHAM UNIVERSITY
2 Methoxy antimycin a derivatives and methods of use
InactiveUS20050239873A1Inhibitory activityInduce apoptosisBiocideOrganic active ingredientsBcl-2 GenesAntimycin A
Disclosed are 2-methoxy antimycin derivatives or analogs that modulate apoptosis by binding to the hydrophobic groove of a Bcl-2 family member protein (e.g., Bcl-2 or BCl-xL). The 2-methoxy antimycin derivatives or analogs are used in disclosed methods for treating apoptosis-associated diseases such as, for example, neoplastic disease (e.g., cancer) or other proliferative diseases associated with the over-expression of a Bcl-2 family member protein.
Owner:FRED HUTCHINSON CANCER RES CENT
Small molecule antagonists of BCL-2 family proteins
InactiveUS20040214902A1Guaranteed long-term securityAntibacterial agentsBiocideChemical synthesisDisease
The present invention relates to naturally occurring and chemically synthesized small molecule antagonists of Bcl-2 family proteins. In particular, the present invention provides gossypol compounds (e.g., isomers, enantiomers, racemic compounds, metabolites, derivatives, pharmaceutically acceptable salts, in combination with acids or bases, and the like) and methods of using these compounds as antagonists of the anti-apoptotic effects of Bcl-2 family member proteins (e.g., Bcl-2, Bcl-XL, and the like). The present invention also provides compositions comprising gossypol compounds and optionally one or more additional therapeutic agents (e.g., anticancer / chemotherapeutic agents). The present invention also provides methods for treating diseases and pathologies (e.g., neoplastic diseases) comprising administering a composition comprising gossypol compounds and optionally one or more additional therapeutic agents (e.g., anticancer / chemotherapeutic agents) and / or techniques (e.g., radiation therapies, surgical interventions, and the like) to a subject or in vitro cells, tissues, and organs.
Owner:RGT UNIV OF MICHIGAN +1
Methods and pharmaceutical compositions for gnrh-II and gnrh-II modulation of t-cell activity, adhesion, migration and extravasation
Methods and compositions comprising GnRH-I and GnRH-II, GnRH-I and GnRH-II antibodies, anti-receptor antibodies, polynucleotide constructs and GnRH-I and GnRH-II analogs for immune enhancement and suppression, prevention and treatment of diseases and conditions characterized by abnormal T-cell activity, treatment of viral and prion-related diseases, and treatment of T-cell related neoplastic diseases are disclosed.
Owner:KOCH YITZHAK PROF +1
Compositions comprising heat shock proteins or alpha(2) macroglobulin, antigenic molecules and saponins, and methods of use thereof
InactiveUS20020037290A1Growth inhibitionEffective amountBiocideSenses disorderAutoimmune ReactionsAutoimmune responses
The present invention relates to pharmaceutical compositions and methods for the prevention and treatment of autoimmune diseases, infectious diseases, neurodegenerative diseases, and primary and metastatic neoplastic diseases. In the practice of the invention, the compositions are employed comprising: (a) a heat shock protein (hsp) or an alpha(2)macroglobulin (alpha2M); (b) a saponin; and, optionally, (c) an antigenic molecule. The antigenic molecule displays the antigenicity of an antigen of: (a) a cell that elicits an autoimmune response; (b) an agent of an infectious disease; (c) a cancerous cell; or (d) a cell or structure associated with a neurodegenerative or amyloid disease. The hsps that can be used in the practice of the invention include but are not limited to hsp70, hsp90, gp96, calreticulin, hsp 110, grp 170, and PDI, alone or in combination with each other. The antigenic molecule can be covalently or noncovalently bound to the hsp or alpha2M, free in solution, and / or covalently bound to the saponin. The compositions of the invention can be administered alone or in combination with the administration of antigen presenting cells sensitized with an hsp- or alpha2M-antigenic molecule complex.
Owner:ANTIGENICS
Compositions and methods of treatment of neoplastic diseases and hypercholesterolemia with citrus limonoids and flavonoids and tocotrienols
Compositions and methods for the prevention and treatment of neoplastic diseases and hypercholesterolemia are described. Individuals at a high risk of developing or having neoplasia or hypercholesterolemia undergoing conventional therapies may be treated with an effective dose of triterpene derivatives in citrus limonoids, polyphenolic flavonoid citrus compounds, tocotrienols or a combination of these agents.
Owner:INTERHEALTH NUTRACEUTICALS
Use of glycosylceramides as adjuvants for vaccines against infections and cancer
InactiveUS7488491B2Enhancement and extension of durationAntibacterial agentsOrganic active ingredientsAdjuvantMammal
The present invention relates to methods and compositions for augmenting an immunogenicity of an antigen in a mammal, comprising administering said antigen together with an adjuvant composition that includes glycosylceramide, preferably α-galactosylceramide (α-GalCer). According to the present invention, the use of glycosylceramide as an adjuvant is attributed at least in part to the enhancement and / or extension of antigen-specific Th1-type responses, in particular, CD8+ T cell responses. The methods and compositions of the present invention can be useful for prophylaxis and treatment of various infectious and neoplastic diseases.
Owner:NEW YORK UNIVERSITY
Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
The invention relates nucleic acids and their encoded polypeptides, whose expression is modulated in cancer or tumor cells. The invention further relates to methods useful for treating or modulating cancer or tumors in mammals in need of such biological effect. This includes the diagnosis and treatment of oncological disorders. Additionally, the present invention further relates to the use of antibodies against the polypeptides of the present invention as diagnostic probes or as therapeutic agents as well as the use of polynucleotide sequences encoding the polypeptides of the present invention as diagnostic probes or therapeutic agents for the treatment of a broad range of pathological states.
Owner:PHARMACIA CORP
A kit for early diagnosis of neoplastic disease, a method and applications of the kit
InactiveCN107893101ASimplify detection stepsImprove reliabilityMicrobiological testing/measurementDiseaseFluorescence
The invention belongs to the technical field of neoplastic disease diagnosis, and discloses a kit for early diagnosis of neoplastic disease, a method and applications of the kit. The kit includes a specific capturing and detecting system for a tumor exosome and a molecular beacon fluorescent detection system. The specific capturing and detecting system for the tumor exosome includes a solution ofa magnetic gold nanosphere composite modified by a tumor exosome specific ligand and adopting ferric ferrous oxide as a core, and a gold nanocage solution modified by the exosome specific ligand. Themolecular beacon fluorescent detection system includes a molecular beacon probe provided with a fluorescent group, fluorescent amplification substrate hybrid chains provided with fluorescent groups and a buffer liquid. The kit and the method combine tumor exosome specific capturing and analysis and a molecular beacon fluorescent detection method, and greatly increases accuracy and reliability of early diagnosis of tumor.
Owner:ZHENGZHOU UNIV
Vinblastine derivative, preparation method of vinblastine derivative, and application of vinblastine derivative in medicines
The invention belongs to the field of pharmaceutical compounds, and relates to a new vinblastine derivative, a preparation method of the vinblastine derivative, a pharmaceutical composition containing the derivative, and application of the vinblastine derivative as a therapeutic agent. The vinblastine derivative provided by the invention is a compound shown in a general formula (I) or salt thereof. The compound provided by the invention or salt thereof can be used as a pharmaceutical ingredient for inhibiting the cell proliferation of mammals or preparing a pharmaceutical composition for treating tumors so as to treat the solid tumor, cancer, lymphoma, Hodgkin's disease, tumor disease, neoplastic disease and the like of mammals.
Owner:FUDAN UNIV
Use of heat shock proteins to enhance efficacy of antibody therapeutics
InactiveUS20060093612A1Good effectReduce morbidityAntibacterial agentsSenses disorderStress ProteinsNeuro-degenerative disease
The present invention relates to methods and pharmaceutical compositions useful for the prevention and treatment of any disease wherein the treatment of such disease would be improved by an enhanced immune response, such as infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), or neurodegenerative or amyloid diseases. In particular, the contemplated invention is directed to method comprising the administration of heat shock / stress proteins (HSPs) or HSP complexes alone or in combination with each other, in combination with the administration of an immunoreactive reagent. The invention also provides pharmaceutical compositions comprising one or more HSPs or HSP complexes in combination with an immunoreactive reagent. Additionally, the invention contemplates the use of the methods and compositions of the invention to enhance or improve passive immunotherapy and effector cell function.
Owner:UNIV OF CONNECTICUT HEALTH CENT
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com